What is BioXcel Therapeutics Debt-to-Equity?
BioXcel Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.35 Mil. BioXcel Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $101.04 Mil. BioXcel Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-56.51 Mil.
BioXcel Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was -1.79.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for BioXcel Therapeutics's Debt-to-Equity or its related term are showing as below:
BTAI'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.79 Med: 0.01 Max: 1.23
Current: -1.79
During the past 8 years, the highest Debt-to-Equity Ratio of BioXcel Therapeutics was 1.23. The lowest was -1.79. And the median was 0.01.
BioXcel Therapeutics Debt-to-Equity Historical Data
The historical data trend for BioXcel Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioXcel Therapeutics Debt-to-Equity Chart
|
BioXcel Therapeutics Annual Data
|
|
Trend |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
0.04 |
0.01 |
0.01 |
1.23 |
-1.79 |
|
BioXcel Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
1.23 |
1.81 |
16.68 |
-2.45 |
-1.79 |
Competitive Comparison of BioXcel Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, BioXcel Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioXcel Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioXcel Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where BioXcel Therapeutics's Debt-to-Equity falls into.
BioXcel Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
BioXcel Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
BioXcel Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioXcel Therapeutics (BioXcel Therapeutics) Business Description
Traded in Other Exchanges
Address
555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Executives
| Vimal Mehta |
director, officer: CEO, President, Secretary |
780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405 |
| Richard I Steinhart |
officer: Chief Financial Officer |
125 ELM STREET, NEW CANAAN CT 06840 |
| Javier Rodriguez |
officer: SEE REMARKS |
C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511 |
| Krishnan Nandabalan |
director, 10 percent owner |
228 VILLAGE POND ROAD, GUILFORD CT 06437 |
| Akrati Agarwal |
10 percent owner |
2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437 |
| Michael James Aiello |
10 percent owner |
10 TEMPLETON ROAD, WALLINGFORD CT 06492 |
| Krunal Dilip Patel |
10 percent owner |
2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437 |
| Alka Sood |
10 percent owner |
2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437 |
| Pardeep Kumar Sood |
10 percent owner |
2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437 |
| Vipin Agarwal |
10 percent owner |
2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437 |
| Rashmi Agarwal |
10 percent owner |
2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437 |
| Jatin Markand Patel |
10 percent owner |
2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437 |
| Bina Jatin Patel |
10 percent owner |
2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437 |
| Diwakar Jain |
10 percent owner |
2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437 |
| Anita Jain |
10 percent owner |
2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437 |
BioXcel Therapeutics (BioXcel Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BTAI has been successfully added to your